Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 2 Study of Decitabine in Combination With Midostaurin (PKC412) for Elderly Patients With Newly Diagnosed FLT3-ITD/TKD Positive Acute Myeloid Leukemia
Sponsor: David Iberri
Terminated
Accrual factor
A PHASE2 clinical study on AML (Adult) With 11q23 (MLL) Abnormalities and AML (Adult) With Del (5q), this trial is terminated or withdrawn. The trial is conducted by David Iberri and has accumulated 9 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Oct 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
▶ Show 4 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Dec 2017 — Apr 2018 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Feb 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jun 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- David Iberri
For direct contact, visit the study record on ClinicalTrials.gov .